TrialsgrambetaRCTs are beautiful

ADVOCATE

2021

Avacopan for ANCA-Associated Vasculitis

In 331 patients with ANCA-associated vasculitis, the oral C5a-receptor antagonist avacopan improved sustained remission at week 52 compared with a tapering prednisone regimen.

Result

Remission at week 26 and sustained remission at week 52
Absolute difference
10.8 points
NNT
10

Absolute difference and NNT are derived from the event rates.

Also reported: Week 26 non-inferior (72.3% vs 70.1%);

Original publication
Subtopic
ANCA vasculitis
Design
Phase 3 double-blind RCT
Relevance
Important: one of several pillars.
Source
Jayne DRW, et al. N Engl J Med. 2021;384(7):599-609.doi 10.1056/NEJMoa2023386

Discussion & critique

Retracted in 2026. Nine primary-endpoint assessments were re-adjudicated after database lock and after unblinding, unknown to the two academic authors, who then asked the NEJM to withdraw the paper. The EMA found the trial in breach of good clinical practice and its data "incorrect and misleading", and the European Commission revoked the EU marketing authorisation in August 2026; the FDA had proposed withdrawal in April. Read as a record of what was claimed, not of what was shown.

Discussed in podcasts